Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: marginmike who wrote (407)	3/12/1999 12:01:00 AM
From: 5,17,37,5,101,...	Respond to of 2515

I bought two years ago for the same reason at $5.00 and have traded it successfully so my basis is around $3.00. My outlook hasn't changed nor has my core position. Simply: C225 is worth about $400MILL as stand alone drug and cancer cocktail ingredient. BEC2 is worth about $150MILL. Ongoing research is worth another $50MILL along with hard assets. 25MILL shares into $500MILL is $20.00/sh. Obviously this assumes BEC2 and C225 work as the company says and assumes no sideswipe competition. My numbers are conservative. Speculation could easily drive this to $30.00 (eg Moors&Cabot target). We will likely see both $10 and $30 Jackson